Skip to search formSkip to main contentSkip to account menu

acifran

Known as: 2-Furancarboxylic acid, 4,5-dihydro-5-methyl-4-oxo-5-phenyl-, 2-methyl-2-phenyl-3(2H)furanone-5-carboxylic acid, 4,5-dihydro-5-methy1-4-oxo-5-pheny1-2-furancarboxylic acid 
An agonist of niacin receptors capable of mimicking niacin's ability to increase high-density lipoprotein (HDL). Acifran produces these effects at… 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

AY 25712

Broader (1)

Furans

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Cloning and characterization of the hamster and guinea pig nicotinic acid receptors April
In this study, we present the identification and characterization of hamster and guinea pig nicotinic acid receptors. The hamster… 
1990
1990
Pharmacokinetics and disposition of the lipid‐lowering drug acifran in normal subjects and in patients with renal failure
The pharmacokinetics and metabolic fate of the antihyperlipidemic drug acifran were assessed after a single oral dose of the 14C… 
1987
1987
Acifran: a double-blind, randomized, placebo-controlled efficacy study in type IIa hyperlipoproteinemic patients.
The antihyperlipoproteinemic agent acifran (AY-25,712) was administered double-blind to 14 Type IIa hyperlipoproteinemic patients… 
1986
1986
The metabolic disposition of acifran, a new antihyperlipidemic agent, in rats and dogs.
The metabolic disposition of the antihyperlipidemic agent acifran (AY-25, 712) was determined in rats and dogs. The synthesis of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)